Nektar Therapeutics (NASDAQ:NKTR) had its price objective boosted by equities research analysts at Mizuho from $30.00 to $45.00 in a report issued on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s target price indicates a potential upside of 4.48% from the company’s previous close.

NKTR has been the topic of a number of other reports. Jefferies Group LLC restated a “buy” rating and issued a $23.00 price target on shares of Nektar Therapeutics in a report on Friday, July 21st. Roth Capital set a $33.00 price target on shares of Nektar Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. Cowen and Company assumed coverage on shares of Nektar Therapeutics in a report on Tuesday, November 7th. They issued an “outperform” rating on the stock. Canaccord Genuity assumed coverage on shares of Nektar Therapeutics in a report on Thursday, November 9th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, BidaskClub cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $34.33.

Nektar Therapeutics (NASDAQ NKTR) traded up $3.51 during trading hours on Tuesday, hitting $43.07. 3,933,600 shares of the stock were exchanged, compared to its average volume of 1,611,002. Nektar Therapeutics has a twelve month low of $11.41 and a twelve month high of $43.15. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.16. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The business had revenue of $152.90 million for the quarter, compared to analysts’ expectations of $126.50 million. During the same period last year, the business earned ($0.32) EPS. The company’s revenue was up 321.2% compared to the same quarter last year. equities research analysts forecast that Nektar Therapeutics will post -0.78 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Nektar Therapeutics (NKTR) PT Raised to $45.00” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/16/nektar-therapeutics-nktr-pt-raised-to-45-00.html.

In other Nektar Therapeutics news, COO John Nicholson sold 15,910 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $37.78, for a total transaction of $601,079.80. Following the completion of the transaction, the chief operating officer now directly owns 249,066 shares of the company’s stock, valued at approximately $9,409,713.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Stephen K. Doberstein sold 396,323 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $29.00, for a total transaction of $11,493,367.00. Following the transaction, the senior vice president now directly owns 52,016 shares of the company’s stock, valued at $1,508,464. The disclosure for this sale can be found here. Insiders sold a total of 941,427 shares of company stock valued at $24,663,626 over the last quarter. 6.10% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of NKTR. Teachers Advisors LLC raised its position in Nektar Therapeutics by 103.8% during the 1st quarter. Teachers Advisors LLC now owns 663,324 shares of the biopharmaceutical company’s stock worth $15,568,000 after buying an additional 337,868 shares during the last quarter. Bank of America Corp DE raised its position in Nektar Therapeutics by 100.0% during the 1st quarter. Bank of America Corp DE now owns 276,642 shares of the biopharmaceutical company’s stock worth $6,493,000 after buying an additional 138,330 shares during the last quarter. HighTower Advisors LLC raised its position in Nektar Therapeutics by 10.4% during the 1st quarter. HighTower Advisors LLC now owns 16,725 shares of the biopharmaceutical company’s stock worth $391,000 after buying an additional 1,569 shares during the last quarter. State of Alaska Department of Revenue raised its position in Nektar Therapeutics by 79.6% during the 2nd quarter. State of Alaska Department of Revenue now owns 30,625 shares of the biopharmaceutical company’s stock worth $598,000 after buying an additional 13,575 shares during the last quarter. Finally, LS Investment Advisors LLC raised its position in Nektar Therapeutics by 8.8% during the 2nd quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 535 shares during the last quarter. 94.97% of the stock is owned by institutional investors.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.